Table 2.

The univariate and multivariate analysis of factors associated with PFS and OS in overall included patients

Factors	N	Univariate analysis						Multivariate analysis
		PFS			OS			PFS			OS
		HR	95%CI	P	HR	95%CI	P	HR	95%CI	P	HR	95%CI	P
Age				0.466			0.596
≤ 50 year	20	1			1
> 50 year	84	1.579	0.462–5.391		1.503	0.333–6.792
Histology				0.018*			0.037*			0.022*			0.038*
High-grade	51	1			1			1			1
Low-grade	53	3.396	1.233–9.354		5.034	1.102–2.905		3.729	1.212–11.474		5.121	1.092–24.010
FIGO stage				< 0.001*			0.092			0.230
Early-stage	75	1			1			1
Late-stage	29	7.411	2.826–19.433		2.557	0.857–7.635		2.644	0.541–12.914
Adjuvant treatment				0.068			0.817
No	42	1			1
Yes	62	2.773	0.926–8.299		0.874	0.279–2.732
Tumor size				0.230			0.937
≤ 2 cm	21	1			1
> 2 cm	83	2.447	0.567–10.553		0.949	0.259–3.479
Invasion depth				0.001*			0.752			0.578
None or < 1/2	59	1			1			1
≥ 1/2	45	6.216	2.076–18.616		1.193	0.400–3.555		1.359	0.461–4.004
LVSI				0.004*			0.312			0.742
No	66	1			1			1
Yes	38	3.896	1.553–9.779		1.760	0.588–5.268		1.218	0.377–3.934
Parametrial involvement				0.316			0.523
No	86	1			1
Yes	18	1.678	0.610–4.620		1.524	0.418–5.554
LN metastasis				0.002*			0.965			0.218
No	86	1			1			1
Yes	18	4.009	1.633–9.844		0.963	0.213–4.360		3.415	0.594–9.821
Distant metastasis				< 0.001*			0.030*			0.496			0.119
No	89	1			1			1			1
Yes	15	7.110	2.922–17.298		3.726	1.139–12.191		2.415	0.475–4.649		2.634	0.779–8.908
Ascites				0.005*			0.977			0.960
No	84	1			1			1
Yes	20	3.511	1.453–8.483		1.020	0.271–3.836		0.965	0.240–3.885
MELF				0.763			0.410
No	92	1			1
Yes	12	1.208	0.354–4.126		0.041	0.000–82.362
TLS				0.002*			0.806			0.003*			0.756
No	23	1						1			1
Yes	81	0.253	0.105–0.609		0.850	0.233–3.098		0.154	0.044–0.536		0.808	0.210–3.102

PFS Progression-free survival; OS overall survival; LVSI lymphovascular space invasion; MELF microcystic, enlarged and fragmented; TLS tertiary lymphoid structures.*p < 0.05